Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03434678Phase 3Completed
Phase 3, randomised, open-label trial (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Incidences of Grade 3 or Greater Complications at 90 days. Started Jan 2018; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03434678.